Cited by 256Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsNeuroscience and Neuropharmacology Research

Amyloid-β Receptors: The Good, the Bad, and the Prion Protein

Open access
Jarosz-Griffiths, Heledd H., Noble, Elizabeth, Rushworth, Jo V., Hooper, Nigel M.·2016·Journal of Biological Chemistry

Abstract

Several different receptor proteins have been identified that bind monomeric, oligomeric, or fibrillar forms of amyloid-β (Aβ). "Good" receptors internalize Aβ or promote its transcytosis out of the brain, whereas "bad" receptors bind oligomeric forms of Aβ that are largely responsible for the synapticloss, memory impairments, and neurotoxicity that underlie Alzheimer disease. The prion protein both removes Aβ from the brain and transduces the toxic actions of Aβ. The clustering of distinct receptors in cell surface signaling platforms likely underlies the actions of distinct oligomeric species of Aβ. These Aβ receptor-signaling platforms provide opportunities for therapeutic intervention in Alzheimer disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.r115.702704

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia.

    “Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9].”
  • Cognitive deficits in mild cognitive impairment patients and decreased executive and reasoning abilities in Alzheimer's disease are caused by oxidative damage of small Aβ oligomers to synaptic membranes.

    “Cognitive deficits in MCI patients and decreased executive and reasoning abilities in AD are caused by the oxidative damage of small Aβ oligomers to the synaptic membranes [83,84,85].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 118 · Cited by 256

Authors
Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V., & Hooper, N. M.
Affiliations
  • University of Manchester (GB)
  • De Montfort University (GB)
Corresponding author
Hooper, Nigel M.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2016-02
Volume
291
Issue
7
Pages
3174-3183
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2202164390
Cited by
256
References
118
Citations by year
2026: 10 · 2025: 14 · 2024: 21 · 2023: 21 · 2022: 31 · 2021: 28 · 2020: 28 · 2019: 37 · 2018: 32 · 2017: 28 · 2016: 6
FWCI
16.21
Type
journal article
Language
en
Open access
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
Funders
  • Alzheimer's Research UK (PG2013–12)
  • Biotechnology and Biological Sciences Research Council
  • Dr. Donald Dean Fund in Dementia Research
  • University of Manchester
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
amyloid-beta oligomers, prion protein, Alzheimer's disease, receptor internalization, transcytosis, synaptic loss, memory impairment, neurotoxicity, therapeutic target
MeSH terms
Receptor for Advanced Glycation End Products, Alzheimer Disease, Animals, Humans, Ligands, Models, Biological, Nerve Tissue Proteins, Neurons, Receptor Aggregation, Receptors, Cell Surface, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Amyloid beta-Peptides, Apoptosis, PrPC Proteins, Nootropic Agents, Protein Isoforms, Low Density Lipoprotein Receptor-Related Protein-1, Transcytosis, Molecular Targeted Therapy, Protein Aggregation, Pathological, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review